After much discussion of the pipeline, cost structure and global opportunities, Levin affirmed one small item on the agenda: Teva is going ahead with a large, late-stage trial of Revascor, an experimental cell therapy for congestive heart failure.
http://news.investors.com/technology/122112-638001-cell-therapy-could-shake-off-provenge-blues.htm
http://news.investors.com/technology/122112-638001-cell-therapy-could-shake-off-provenge-blues.htm
No comments:
Post a Comment